Context Matrix metalloproteinases (MMPs) are associated with diastolic dysfunction and heart failure in acquired heart disease. Objective To investigate the role of MMPs as novel biomarkers in clinically stable adults with congenital heart disease. Methods We measured serum MMP-2, -3, -9 and tissue inhibitor of matrix metalloproteinase-1 in 425 patients and analysed the association with cardiac function and exercise capacity. Results MMP-2 was significantly associated with exercise capacity, ventilatory efficiency and left ventricular deceleration time, independently of age, sex, body surface area and NT-proBNP. Conclusion MMP-2 may provide new information in the clinical evaluation of adults with congenital heart disease.

, ,
doi.org/10.3109/1354750X.2016.1153722, hdl.handle.net/1765/91715
Biomarkers
Department of Cardiology

Baggen, V., Eindhoven, J., van den Bosch, A., Witsenburg, M., Cuypers, J., Langstraat, J. S., … Roos-Hesselink, J. (2016). Matrix metalloproteinases as candidate biomarkers in adults with congenital heart disease. Biomarkers, 21(5), 466–473. doi:10.3109/1354750X.2016.1153722